Осложнения сахарного диабета: фокус на диабетическую нейропатию
Аннотация
Обсуждается одно из частых осложнений сахарного диабета – диабетическая нейропатия, которая характеризуется ранней инвалидизацией пациентов, ухудшением качества жизни. Самой распространенной клинической формой является дистальная нейропатия. Рассматриваются вопросы патогенеза, клиническая картина, лечение с применением витаминов группы В.
Об авторе
Е. В. Бирюкова
Московский государственный медико-стоматологический университет им. А.И. Евдокимова Минздрава России
Россия
Доктор медицинских наук, профессор
Россия
Доктор медицинских наук, профессор
Список литературы
1. Бородулина И.В., Рачин А.П. Полинейропатии в практике врача: особенности патогенеза, клиники и современные подходы к лечению болевых и безболевых форм. РМ, 2016, 25: 1705-1710.
2. Морозова Т.Е., Дурнецова О.С. Мед. Совет, 2014, 18: 72-77.
3. Berrone E, Beltramo E, Solimine C, Ape AU et al. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem, 2006, 14: 9307–9313.
4. Boulton AJM, Vileikyte L, Ragnarson-Tennwall G, Apelqvist J. The global burden of diabetic foot disease. Lancet, 2005a, 366: 1719–1724.
5. Boulton AJM, Vinik AI, Arezzo JC et al. Diabetic neuropathy. A statement by the American Diabetes Association. Diabetes Care, 2005b, 28: 956–962.
6. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes, 2005, 54: 1615–1625.
7. Elgayar SAM, Eltony SA, Sayed AA. Protective effect of vitamin B complex in diabetic peripheral neuropathy. Histopathological study. Eur J Anat, 2017, 21(3): 173-18.
8. Gonzalez-Ortiz M, Martinez-Abundis E, RoblesCervantes JA et al. Effect of thiamine administration on metabolic profile, cytokines and inflammatory markers in drug-naive patients with type 2 diabetes. Eur J Nutr, 2011, 50(2): 145–149.
9. Happich M, John J, Stamenitis S, Clouth J, Polnau D. The quality of life and economic burden of neuropathy in diabetic patients in Germany in 2002–results from the Diabetic Microvascular Complications (DIMICO) study. DiabetesRes Clin Pract, 2008, 81: 223–230.
10. Herman WH, Kennedy L for the GOAL A1c study. Underdiagnosis of peripheral neuropathy in type 2 diabetes. Diabetes Care, 2005, 28: 1480–1481.
11. IDF http://www.diabetesatlas.org.
12. Kempler P (ed). Neuropathies. Pathomechanism, clinical presentation, diagnosis, therapy. Budapest: Springer Scientific Publisher, 2002.
13. Kibirige D, Mwebaze R. Vitamin B12 deficiency among patients with diabetes mellitus: is routine screening and supplementation justified? Journal of Diabetes & Metabolic Disorder,2013, 12. http://www.jdmdonline.com/content/12/1/17.
14. Mooney S, Leuendorf J-E, Hendrickson C, Hellmann H. Vitamin B6: a long known compound of surprising complexity. Molecules, 2009, 14: 329-351.
15. Pop-Busui R, Boulton AJM, Feldman EL. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care, 2017, 40(1): 136-154. https://doi.org/10.2337/dc16-2042.
16. Rabbani N, Shahzad Alam S, Riaz et al. Highdose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a pilot randomized, double-blind placebo-controlled study. Diabetologia, 2009, 52: 208–212.
17. Rizvi A, Ahmad A, Rizvi Z. Efficacy of Combination of Vitamin B1, B6 and B12 in Management of Diabetic Peripheral Neuropathy. P J M H S, 2013, 7(3): 801-803.
18. Solomon LR. Disorders of cobalamin (vitamin B12) metabolism: emerging concept in patophysiology, diagnosis and treatment. Blood Rev, 2007, 21: 113-130.
19. Sun Y, Lai M, Lu C: Effectiveness of Vitamin B12 on Diabetic Neuropathy: Systematic Review of Clinical Controlled Trials. Acta Neurol Taiwan, 2005, 14: 48-54.
20. Tesfaye S et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care, 2010, 33: 2285–2293.
21. Thornalley PJ. The potential role of thiamine (vitamin B1) indiabetic complications. Curr Diabetes Rev, 2005, 1: 287–298.
22. Thornalley PJ, Babaei-Jadidi R, Al Ali H et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia, 2007, 50: 2164–2170.
23. Zeng L, Alongkronrusmee D, van Rijn RM. An integrated perspective on diabetic, alcoholic, and drug-induced neuropathy, etiology, and treatment in the US. J Pain Res, 2017, 10: 219228.
24. Zhao J, Zhong CJ. A review on research progress of transketolase. Neurosci Bull. 2009, 25(2):94–99
25. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come? Diabetes Care, 2008, 31: S255–S261.
Для цитирования:
Бирюкова Е.В. Осложнения сахарного диабета: фокус на диабетическую нейропатию. Медицинский Совет. 2018;(4):48-52. https://doi.org/10.21518/2079-701X-2018-4-48-52
For citation:
Biryukova E.V. Complications in diabetes mellitus: diabetic neuropathy focus. Meditsinskiy sovet = Medical Council. 2018;(4):48-52. (In Russ.) https://doi.org/10.21518/2079-701X-2018-4-48-52
Просмотров: 446
Послать статью по эл. почте 
